Feb 5 GlaxoSmithKline Plc CEO Andrew Witty
* CEO says European respiratory business remains extremely
* CEO says new generics to Advair not substitutable in many
* CEO says U.S. Advair generics "some distance in the future"
* CEO says pleased with Breo start
* CEO says nine potential respiratory launches coming through
* CEO says long-term trend in emerging markets still upwards,
volatility; view remains undimmed
* CEO says darapladib and mage-3 drugs remain "intriguing"
* CEO says will file malaria vaccine